A perfect storm of clinical setbacks, intensifying competition, and internal upheaval has triggered a historic sell-off in ...
Stocktwits on MSN
The 2025 weight-loss drug gold rush: How Eli Lilly pulled ahead, Novo hit a snag — and a swarm of biotech underdogs are closing in
Global obesity-drug sales could exceed $130–150B by the mid-2030s, driven by GLP-1/GIP drugs and expanding access beyond the ...
Fruergaard og Gubra-stifter lægger mio. i opkøb af jordFlere prominente erhvervsfolk har lagt millioner i en nystiftet fond, ...
Erhvervsprofiler sender millioner i ny fond til opkøb af jordFlere prominente erhvervsfolk har lagt millioner i en nystiftet fond, der vil satse på et brandvarmt emne disse dage, nemlig jord. Planetar ...
Godt nok blev Rebien valgt til formand med 92,25 procent af de samlede stemmer på den ekstraordinære generalforsamling den 14. november, men da han også er formand for Novo Nordisk Fonden, var han ...
Amycretin also improved participants’ blood sugar levels in positive sign for Danish company’s treatment pipeline ...
Shares of Novo Nordisk plunged after the Danish pharmaceutical company said a highly anticipated trial for Alzheimer's disease failed to meet its main goal.
Novo Nordisk is quietly coming out of the storm despite the prevailing pessimism, especially among retail investors. Thanks to Wegovy's approval as a treatment for NASH, its sales rose to DKK 20.35 ...
A dramatic corporate governance battle reached its climax at Novo Nordisk on Friday when the company’s majority shareholder forced a complete boardroom overhaul. The Novo Nordisk Foundation, which ...
Lars Rebien Sorensen is back as chairman of Novo Nordisk A/S following a shareholder meeting that exposed the depth of rivalry between the Danish drugmaker and US arch nemesis Pfizer Inc. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback